No abstract available.
Drug Therapy* ; Uterine Cervical Neoplasms*

No abstract available.
Bleomycin* ; Drug Therapy* ; Humans ; Uterine Cervical Neoplasms*

No abstract available.
Drug Therapy* ; Humans ; Uterine Cervical Neoplasms*

No abstract available.
Drug Therapy* ; Methotrexate* ; Uterine Cervical Neoplasms*

No abstract available.
Female ; Humans ; Leiomyoma/*therapy ; Magnetic Resonance Imaging, Interventional/*methods ; Uterine Artery Embolization/*methods ; Uterine Neoplasms/*therapy

*Adenocarcinoma ; *Carcinosarcoma ; *Hysterectomy ; *Neoplasm Metastasis ; Neoplasms/*diagnosis ; Neoplasms/*etiology ; Neoplasms/*radiotherapy ; Neoplasms/*therapy ; *Uterine Neoplasms

The treatment of patients with bulky stage IB2 cervical cancer is a therapeutic challenge. Neither of local treatment such as radical hysterectomy nor primary radiation therapy is sufficiently effective, and also is associated with significant treatment-related complications. A number of phase III studies have investigated alternative management approaches in this patient population. Consistent with results seen in locally advanced cervical cancer, chemoradiation therapy is superior to radiation therapy alone as primary treatment for stage IB2 cervical cancer, and as adjuvant therapy for surgically treated patients with high-risk factors for recurrence. Neoadjuvant chemotherapy has resulted in high clinical response rates and operability rates in patients with stage IB2 cervical cancer. There are two phase III clinical trials suggesting an improvement in survival with neoadjuvant chemotherapy followed by radical hysterectomy versus either surgery (and/ or postoperative radiation) or radiation therapy alone. Pretreatment laparoscopic surgical staging in stage IB2 cervical cancer can be used as a guideline for individualized therapy. These emerging treatments should be investigated in prospective controlled trials.
Drug Therapy ; Humans ; Hysterectomy ; Recurrence ; Uterine Cervical Neoplasms*

This study is to evaluate therapeutic effects between interferon-a combined chemotherapy and chemotherapy(5-fluorouracil, cisplatin) only in invasive uterine cervical cancer. The study included 35 cases of interferon-a combined chemotherapy group and 50 cases of chemotherapy(5-FU, cisplatin) only group. Then we analyzed the therapeutic effects with respect to size of tumor, number of lymphocyte subsets and NK activity, and SCC Ag(squamous cell carcinoma antigen) level in peripheral blood. (continue)
Drug Therapy* ; Humans ; Lymphocyte Subsets ; Uterine Cervical Neoplasms*

No abstract available.
Cisplatin* ; Drug Therapy* ; Humans ; Hysterectomy* ; Mitomycin* ; Uterine Cervical Neoplasms*

OBJECTIVE: To characterize the clinical features of platinum compounds (cisplatin plus carboplatin) associated hypersensitivity reactions. METHODS: Medical records of 102 patients with gynecologic malignancy who received chemotherapy based on platinum at Center for Uterine Cancer from Jun. 2001 to Nov. 2002 were analyzed. Platinum hypersensitivity reaction was classified as acute and delayed reaction according to the time of onset, also mild and severe reaction according to the severity of symptoms and signs. RESULTS: Among the 102 patients treated with platinum compounds during this period, 20 (20%) developed hypersensitivity reaction. The median number of platinum courses for the first episode was 7 (range 4-9) and it concentrated at 7, 8, 9th cycles. Fourteen patients developed acute reaction and six patients experienced delayed reaction. Ten patients experienced severe symptoms including dyspnea. Acute reaction developed from a few minutes to 30 minutes after the initiation of the platinum infusion. Delayed reaction developed after discharge of patients with mild intensity. CONCLUSION: Platinum hypersensitivity reactions develop in patients who have been extensively pre- treated with these agents. As platinum compounds are increasingly used as neoadjuvant, initial, second-line chemotherapy of ovarian cancer and concurrent chemoradiation, palliative setting of cervical cancer, it can be anticipated that hypersensitivity reactions to these drugs will happen more frequently, at the same time it might be a important issue for clinicians engaged in chemotherapy.
Carboplatin* ; Cisplatin* ; Drug Therapy ; Dyspnea ; Humans ; Hypersensitivity* ; Medical Records ; Ovarian Neoplasms ; Platinum ; Platinum Compounds ; Uterine Cervical Neoplasms ; Uterine Neoplasms